Form 4 for SMMT Summit Therapeutics Inc.
Accepted 2024-09-13 00:00:00 ET · period of report 2024-09-11 · accession 0001599298-24-000139 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-13 | 2024-09-11 | SMMT | DUGGAN ROBERT W | Co-CEO, Dir, 10% | A - Grant | $22.70 | +3.33M | 551.70M | +0.6% | +$75.50M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-11 | A | A | 3,325,991 | $22.70 | 551,695,096 | D | — | — | (F1) Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of September 11, 2024, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person at a purchase price of $22.70 per share. The transaction closed on September 13, 2024. (F2) Excludes shares underlying options and warrants held by the Reporting Person. |